Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006705 | 1.00 | NR1H2 (0.66) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL30468491 | 0.89 | NR1H2 (0.68) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL446262 | 0.86 | NR1H2 (0.64) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL29507872 | 0.86 | NR1H2 (0.64) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL12283366 | 0.85 | ESR2 (0.48) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL29390606 | 0.85 | ESR2 (0.48) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL31075233 | 0.84 | ESR2 (0.47) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL22993203 | 0.83 | ESR2 (0.46) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL29388532 | 0.83 | ESR2 (0.46) | NR1H2ESR2USP30HDAC1DDB1 | |
| SCHEMBL31075276 | 0.82 | ESR2 (0.46) | NR1H2ESR2USP30HDAC1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347592-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | Aprea Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117720541-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-111902413-B | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2022256680-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ATRIN PHARMACEUTICALS (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | NR1H2 4452/4885ESR2 3367/4885USP30 3272/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | NR1H2 4452/4885ESR2 3367/4885USP30 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.